IMVT insider trading
NasdaqGS HealthcareImmunovant, Inc.: insider trade history from SEC Form 4 filings.
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Company website: immunovant.com
IMVT insider activity at a glance
FilingIQ tracks 379 insider transactions for IMVT in filings since Dec 20, 2019. The most recent transaction is dated Oct 2, 2026.
Across the full history, 13 open-market purchases
and 253 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IMVT insider trades is 60.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest IMVT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading IMVT
13F funds holding IMVT
Frequently asked
- How many insider trades does FilingIQ track for IMVT?
- FilingIQ tracks 379 Form 4 insider transactions for IMVT (Immunovant, Inc.), covering filings from Dec 20, 2019 onwards. 11 of those are dated within the last 90 days.
- Are IMVT insiders net buyers or net sellers?
- Across the full Form 4 history for IMVT, 13 transactions (3%) were open-market purchases and 253 (67%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IMVT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is IMVT in?
- Immunovant, Inc. (IMVT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.64B.
Methodology & sources
Every IMVT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.